NHS gets 12 years to roll out new weight-loss drug
A new weight-loss jab will be rolled out on the NHS in England - but it could take 12 years for everyone to receive it, the ...
Britain drug-cost watchdog says it will recommend Lilly obesity drug
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made ...
STAT4h
U.K. to restrict Eli Lilly’s obesity drug to patients with greatest need
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
Health Care Flat on Biotech, Obesity-Drug Hopes — Health Care Roundup
Health-care companies were flat, hovering near all-time highs amid optimism about the biotech and obesity-drug niches. In the first head-to-head test, Eli Lilly's Zepbound obesity drug helped people ...
Experts Say GLP-1 Drugs Have Potential Use Beyond Weight Loss
Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...
FiercePharma5h
For first phase of Mounjaro's obesity rollout in England, only a limited number of patients will have access
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...
MedPage Today6h
Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...
Becker's Hospital Review7h
The race to create an oral GLP-1 obesity drug: 4 things to know
The push to develop the first oral GLP-1 receptor drug for obesity is heating up, as four phase 3 drugs race to become the first approved oral treatment for obesity, Global Data reported Dec. 2. Here ...
Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows
New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new ...
STAT8h
‘Leptin’s last chance’: Mouse study says infamous weight loss drug failure could boost GLP-1s
Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...
Health.com9h
Can’t Afford Ozempic, Other GLP-1 Drugs? Here’s What to Do, According to Experts
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
MM&M9h
Lilly’s Zepbound tops Novo Nordisk’s Wegovy in head-to-head obesity study
The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.